Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells

Infection and Immunity

Volumn 69, Issue 9, 2001, Pages 5716-5725

  George Chandy, A ^a   Eriksson, K ^a   Lebens, M ^a   Nordstrom I ^a   Schon E ^a   Holmgren, J ^a  

^a Department of Medical Microbiology ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CARRIER PROTEIN; CD40 ANTIGEN; CD86 ANTIGEN; CELL SURFACE RECEPTOR; CHOLERA TOXIN B SUBUNIT; GAMMA INTERFERON; GANGLIOSIDE GM1; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CONJUGATION; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE FUSION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD86; CHOLERA TOXIN; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; OVALBUMIN; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

EID: 0034873558     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.9.5716-5725.2001     Document Type: Article

References (56)

1. A genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit
2. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes
3. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli
4. Insertion of a HIV-1-neutralizing epitope in surface-exposed internal region of the cholera toxin B-subunit
5. Dendritic cells and the control of immunity
6. Incorporation of cells into an ELISA system enhances antigen-driven lymphokine detection
7. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
8. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates
9. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro
10. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues
11. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans
12. Successful T cell priming in B cell-deficient mice
13. Peripheral tolerance of CD4 T-cells following local activation in adolescent mice
14. Cyclic AMP-independent effects of cholera toxin on B cell activation. II. Binding of ganglioside GM1 induces B cell activation
15. B cells turn off virgin but not memory T cells
16. ompT encodes the Escherichia coli outer membrane protease that cleaves T7 RNA polymerase during purification
17. Oral vaccination, mucosal immunity and oral tolerance with special reference to cholera toxin
18. Interaction of cholera toxin and toxin derivatives with lymphocytes
19. Generation of large numbers of dendritic cells from mouse bote marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
20. + single positive cells with a class II major histocompatibility complex-restricted receptor
21. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12
22. Lack of orally induced systemic unresponsiveness in IFN-γ knockout mice
23. Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines
24. Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation
25. Membrane traffic and the cellular uptake of cholera toxin
26. Expression in Excherichia coli of two mutated genes encoding the cholera toxin B subunit
27. Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen
28. The major histocompatibility complex-restricted antigen receptor on T cells. IV. An antiidiotypic antibody predicts both antigen and I-specificity
29. Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzymatically active A subunit
30. + T cells
31. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response
32. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate
33. 10 thymocytes in vivo
34. Potent immunogenicity of the B subunits of Escherichia coli beat-labile enterotoxin: Receptor binding is essential and induces differential modulation of lympbocyte subsets
35. Cytokines induce the development of functionally heterogeneous T helper cell subsets
36. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
37. Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice
38. Synthesis in Vibrio cholerae and secretion of hepatitis B virus antigen fused to Escherichia coli heat-labile enterotoxin subunit B
39. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming
40. The B-subunit of cholera toxin induces immunoregulatory cells and prevents diabetes in the NOD mouse
41. Antigen-specific T cell activation and proliferation during oral tolerance induction
42. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
43. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice
44. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit
45. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-β-secreting cells and suppressing chemokine expression
46. Identification of Escherichia coli heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure
47. Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin
48. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells
49. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine
50. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model
51. Expanding dendritic cells in vivo enhances the induction of oral tolerance
52. Bone-marrow derived macrophages: Development and regulation of differentiation markers by colony-stimulating factor and interferons
53. The costimulatory function of antigen-presenting cells
54. Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor
55. Suppressive versus stimulatory effects of allergen/cholera toxoid (CTB) conjugates depending on the nature of the antigen in a murine model of type I allergy
56. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: Studies with OVA and human cartilage gp-39